Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4909130 | 0.73 | — | — | |
| SCHEMBL4794205 | 0.73 | CYP1A2 (0.30) | NPC1RAB9ACYP1A2CYP2D6CYP19A1 | |
| SCHEMBL2340955 | 0.72 | — | — | |
| SCHEMBL467328 | 0.71 | MDM2 (0.35) | MDM2NPC1RAB9AKDM4EMAPT | |
| SCHEMBL5503401 | 0.69 | CYP1A2 (0.33) | NPC1RAB9ACYP1A2CYP2D6CYP19A1 | |
| SCHEMBL3082762 | 0.68 | NPC1 (0.42) | MDM2NPC1RAB9AKDM4EMAPT | |
| SCHEMBL155358 | 0.68 | KDM4E (0.52) | NPC1RAB9AKDM4EMAPTCYP1A2 | |
| SCHEMBL1925074 | 0.68 | GOT1 (0.33) | — | |
| SCHEMBL223116 | 0.68 | CYP1A2 (0.32) | NPC1RAB9AKDM4ECYP1A2CYP2D6 | |
| SCHEMBL9199874 | 0.68 | SCN9A (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166134-B | Pyrrolidone derivatives as formyl peptide 2 receptor agonists | 百时美施贵宝公司 | 2024-06-14 | — | — | CN | claimed |
| US-20080138282-A1 | imaging agents for the cyclooxygenase (COX-2) enzyme using positronemission tomograpy (PET); C11 or F18 radioisotopes; inflammatory, cancer, diabetes, neurodegenerative diseases | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-06-12 | — | — | US | claimed |
| WO-2005120584-A2 | RADIOLABELED ARYLSULFONYL COMPOUNDS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2005-12-22 | — | — | WO | claimed |
| CN-109715631-B | TRAF6 inhibitors | 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） | 2022-02-18 | — | — | CN | disclosed |
| CN-107207741-B | Antioxidant-infused ultra-high molecular weight polyethylene | 捷迈有限公司 | 2021-05-11 | — | — | CN | disclosed |
| CN-105611930-B | Spiro quinoxaline derivatives as non-apoptotic regulated cell death inhibitors | 亥姆霍兹慕尼黑中心-德国环境与健康研究中心（股份有限公司） | 2021-03-02 | — | — | CN | disclosed |
| CN-107001806-B | Sphingosine-1-phosphate receptor modulators for the treatment of cardiopulmonary diseases | 斯克利普斯研究院 | 2020-12-04 | — | — | CN | disclosed |
| EP-2699561-B1 | ANDROGEN RECEPTOR MODULATING CARBOXAMIDES | ORION CORP (FI) | 2015-06-03 | — | — | EP | disclosed |
| EP-2029570-B1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-15 | — | — | EP | disclosed |
| EP-2699561-A1 | ANDROGEN RECEPTOR MODULATING CARBOXAMIDES | Orion Corporation (FI) | 2014-02-26 | — | — | EP | disclosed |
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| WO-2012143599-A1 | ANDROGEN RECEPTOR MODULATING CARBOXAMIDES | ORION CORPORATION (FI) | 2012-10-26 | — | — | WO | disclosed |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
| WO-2009122148-A1 | FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009071890-A1 | TRICYCLIC KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071895-A1 | FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| EP-2029570-A1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-04 | — | — | EP | disclosed |
| US-20080138282-A1 | imaging agents for the cyclooxygenase (COX-2) enzyme using positronemission tomograpy (PET); C11 or F18 radioisotopes; inflammatory, cancer, diabetes, neurodegenerative diseases | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2007141504-A1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2005120584-A2 | RADIOLABELED ARYLSULFONYL COMPOUNDS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080138282-A1 | imaging agents for the cyclooxygenase (COX-2) enzyme using positronemission tomograpy (PET); C11 or F18 radioisotopes; inflammatory, cancer, diabetes, neurodegenerative diseases | PTGES2, PTGES, PTGS2 | MDM2 1463/4885NPC1 3083/4885RAB9A 4008/4885 |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | PIKFYVE, PI4KA, PIK3CA | MDM2 1055/4885NPC1 3855/4885RAB9A 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.